C4 Therapeutics (NASDAQ:CCCC – Get Free Report) and Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.
Institutional and Insider Ownership
78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 5.6% of C4 Therapeutics shares are held by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and target prices for C4 Therapeutics and Tenaya Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| C4 Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
| Tenaya Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
C4 Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 195.65%. Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 969.52%. Given Tenaya Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than C4 Therapeutics.
Risk & Volatility
C4 Therapeutics has a beta of 3.07, indicating that its share price is 207% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.87, indicating that its share price is 187% more volatile than the S&P 500.
Profitability
This table compares C4 Therapeutics and Tenaya Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| C4 Therapeutics | -289.44% | -45.45% | -30.90% |
| Tenaya Therapeutics | N/A | -83.75% | -66.53% |
Valuation and Earnings
This table compares C4 Therapeutics and Tenaya Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| C4 Therapeutics | $35.95 million | 9.84 | -$104.99 million | ($1.00) | -2.88 |
| Tenaya Therapeutics | $1.33 million | 62.82 | -$90.60 million | ($0.53) | -0.71 |
Tenaya Therapeutics has lower revenue, but higher earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Tenaya Therapeutics beats C4 Therapeutics on 10 of the 15 factors compared between the two stocks.
About C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
About Tenaya Therapeutics
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
